Please select the option that best describes you:
What neoadjuvant therapy will you give to a premenopausal woman with cT2N0 metaplastic triple negative breast cancer?
Answer from: Medical Oncologist at Academic Institution
A stage 2 metaplastic TNBC is considered a high risk, relatively chemorefractory rare subtype case with limited data regarding optimal treatment. Multiple studies have shown metaplastic tumors demonstrate higher levels of PDL1. (Grabenstetter et al., PMID 34115674) Sylvia Adams has published some re...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I completely agree with Dr. @Hatem H. Soliman. Given the high risk nature of her cancer and younger age, I would follow the KEYNOTE-522 regimen. We understand that metaplastic tumors are less responsive to chemotherapy but our current approach is to treat these tumors like non-metaplastic triple neg...
Comments
Medical Oncologist at NYU Winthrop Hospital
AC-T with Pembrolizumab.
AC-T with Pembrolizumab.
Answer from: Medical Oncologist at Academic Institution
I agree with the above comments (excluding Dr. @Ali's suggestion to give AC-T with pembrolizumab - omitting carboplatin would be a mistake as this is likely to reduce achievement of pCR and compromise long-term outcomes, based on results from a number of trials, including the one presented by Gupta ...